#Sweden #Lund #Hansa Biopharma #Chief Medical Officer #Dr. Philipson

Hansa Biopharma Welcomes Dr. Richard Philipson as New CMO

Hansa Biopharma AB, a pioneering biopharmaceutical company focused on drug development for rare immunological conditions, has made a strategic move by appointing Dr. Richard Philipson as its new Chief Medical Officer (CMO). Effective from July 14, 2025, Dr. Philipson brings over 25 years of industry expertise to the position, marking an exciting new chapter for the company.

Dr. Philipson's Background and Expertise

Dr. Philipson has an impressive track record in the biopharmaceutical sector, including crucial roles in drug development that led to four successful product approvals. His areas of expertise encompass not only rare diseases and gene therapy but also the regulatory strategies vital for navigating complex clinical landscapes. Prior to his role at Hansa, he served as CMO for Calliditas Therapeutics and has held significant positions at GlaxoSmithKline (GSK) for 16 years, where he excelled as Therapeutic Area Head in their Rare Diseases Unit. Dr. Philipson's background extends to Takeda and includes a tenure at Trizell as CMO.

Strategic Significance of the Appointment

CEO Renée Aguiar-Lucander expressed her enthusiasm about Dr. Philipson joining the executive management team. His extensive experience is expected to infuse new vigor into Hansa’s development strategies as the company prepares for its next critical phase in clinical development. According to Aguiar-Lucander, Philipson’s past involvement in both early-stage trials and post-approval studies positions him uniquely to help steer the company’s innovative pipelines in rare diseases, inflammation, and oncology.

Vision for Hansa's Future

Dr. Philipson shared his excitement about this new opportunity, stating that he eagerly anticipates collaborating with the exceptional team at Hansa. His ambition is to leverage his extensive experience as they work on upcoming regulatory submissions and strategize plans for future therapeutic indications. This commitment underscores Hansa's dedication to advancing treatments that address significant unmet medical needs in patients suffering from rare immunological diseases.

About Hansa Biopharma

Hansa Biopharma, headquartered in Lund, Sweden, is listed on Nasdaq Stockholm under the ticker symbol HNSA. The company’s mission is to develop innovative therapies aimed at transforming the lives of patients with rare immunological conditions. Hansa’s proprietary IgG-cleaving enzyme technology platform has laid the groundwork for significant advancements in autoimmune diseases, gene therapies, and transplantation outcomes. Their portfolio includes groundbreaking medications such as imlifidase, which serves as an immunoglobulin G (IgG) antibody-cleaving enzyme therapy, especially beneficial for kidney transplant patients.

As Hansa Biopharma enters this new era under Dr. Philipson’s leadership, stakeholders are eager to see how his contributions will enhance the company’s innovative efforts moving forward, solidifying its place in the biopharmaceutical landscape.

For more information about Hansa Biopharma and their upcoming projects, visit Hansa Biopharma's website and follow them on LinkedIn to stay updated on the latest developments.